Hepatitis C virus (HCV) represents the major risk factor for mixed cryoglobulinemia (MC), a small-vessel vasculitis that may evolve into an overt B-cell non-Hodgkin’s lymphoma. Here, we aimed to identify a biomarker signature for the early diagnosis of minimal residual disease (MRD). We assessed free light chains (FLCs), IgM k,and IgM λ heavy/light chain (HLC) pairs, and vascular endothelial growth factor (VEGF) in sera from 34 patients with MC vasculitis (32 HCV- and 2 HBV-related), treated with low-dose rituximab (RTX). FLCs and IgM HLCs were measured by turbidimetric assay; VEGF by an enzyme-linked immunosorbent assay. After RTX, the positive (complete + partial) clinical and laboratory responses were of85.29% and 50%, respectively; in contrast, the mean levels of FLCs, IgM HLCs, and VEGF were substantially unaffected in most patients and still above the normal range. In those achieving a reduction of FLCs and IgM k and λ chains values within the range of normality, we found that post-treatment free λ chains and IgM k values correlated with clinical and laboratory response. Our results suggest that high levels of FLCs, IgM HLCs, and VEGF could represent the signature of “dormant” B cell clones’ activity that could be very useful to identify MRD indicative of possible relapse or worsening outcome.

Biomarkers of minimal residual disease in rituximab-treated patients with mixed cryoglobulinemia / Basile, Umberto; Gulli, Francesca; Napodano, Cecilia; Pocino, Krizia; Basile, Valerio; Marrapodi, Ramona; Colantuono, Stefania; Todi, Laura; Marino, Mariapaola; Ludovico Rapaccini, Gian; Visentini, Marcella. - In: BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY. - ISSN 0885-4513. - (2020).

Biomarkers of minimal residual disease in rituximab-treated patients with mixed cryoglobulinemia

Ramona Marrapodi;Stefania Colantuono;Marcella Visentini
Ultimo
2020

Abstract

Hepatitis C virus (HCV) represents the major risk factor for mixed cryoglobulinemia (MC), a small-vessel vasculitis that may evolve into an overt B-cell non-Hodgkin’s lymphoma. Here, we aimed to identify a biomarker signature for the early diagnosis of minimal residual disease (MRD). We assessed free light chains (FLCs), IgM k,and IgM λ heavy/light chain (HLC) pairs, and vascular endothelial growth factor (VEGF) in sera from 34 patients with MC vasculitis (32 HCV- and 2 HBV-related), treated with low-dose rituximab (RTX). FLCs and IgM HLCs were measured by turbidimetric assay; VEGF by an enzyme-linked immunosorbent assay. After RTX, the positive (complete + partial) clinical and laboratory responses were of85.29% and 50%, respectively; in contrast, the mean levels of FLCs, IgM HLCs, and VEGF were substantially unaffected in most patients and still above the normal range. In those achieving a reduction of FLCs and IgM k and λ chains values within the range of normality, we found that post-treatment free λ chains and IgM k values correlated with clinical and laboratory response. Our results suggest that high levels of FLCs, IgM HLCs, and VEGF could represent the signature of “dormant” B cell clones’ activity that could be very useful to identify MRD indicative of possible relapse or worsening outcome.
2020
biomarkers, HCV, mixed cryoglobulinemia, rituximab, minimal residual disease, free light chains, IgM heavy/light chains, vascular endothelial growth factor
01 Pubblicazione su rivista::01a Articolo in rivista
Biomarkers of minimal residual disease in rituximab-treated patients with mixed cryoglobulinemia / Basile, Umberto; Gulli, Francesca; Napodano, Cecilia; Pocino, Krizia; Basile, Valerio; Marrapodi, Ramona; Colantuono, Stefania; Todi, Laura; Marino, Mariapaola; Ludovico Rapaccini, Gian; Visentini, Marcella. - In: BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY. - ISSN 0885-4513. - (2020).
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1407232
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact